Trials / Completed
CompletedNCT01729676
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation
Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation: FACT STUDY
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 315 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Degarelix or GnRH agonist | Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-05-01
- Completion
- 2014-05-01
- First posted
- 2012-11-20
- Last updated
- 2014-07-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01729676. Inclusion in this directory is not an endorsement.